Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: Relation with their sensitivity to CTP-11

Anticancer Research

Volumn 21, Issue 1 A, 2001, Pages 471-476

  Lansiaux, A ^a   Bras Goncalves, R A ^a   Rosty, C ^a   Laurent Puig, P ^a   Poupon, M F ^a   Bailly, C ^a  

^a INSERM   (France)

Author keywords

Colorectal cancer; CPT 11; MSI; P53; Topoisomerase I; Xenograft

Indexed keywords

DNA TOPOISOMERASE; IRINOTECAN; PROTEIN P53;

ARTICLE; CHEMOSENSITIVITY; COLORECTAL CANCER; COMPLEX FORMATION; COVALENT BOND; DNA STRAND BREAKAGE; DRUG EFFECT; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; ENZYME INHIBITORS; GENES, P53; HUMANS; MACROMOLECULAR SUBSTANCES; MICE; MICE, NUDE; MICROSATELLITE REPEATS; MUTATION; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035062017     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. CPT-11 in gastrointestinal cancer
2. Weekly irinotecan, leucovorin, and fluorouracil is superior to daily x5 LV/FU in patients with previously untreated metastatic colorectal cancer
3. A randomized phase II trial comparing irinotecan + 5FU/folinic acid to the same schedule of 5FU/FA in patients with metastatic colorectal cancer as front line chemotherapy
4. Clinical applications of the camptothecins
5. Clinical Pharmacology of camptothecins
6. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
7. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen
8. Determinants of CPT-11 and SN-38 activities in human lung cancer cells
9. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status
10. Alternative genetic pathways in colorectal carcinogenesis
11. p53 status and the efficacy of cancer therapy in vivo
12. p53 point mutation and survival in colorectal cancer patients
13. Analysis of topoisomerase I/DNA complexes in patients administered topotecan
14. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation
15. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors
16. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines
17. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites
18. Stabilization of type I topoisomeraseDNA covalent complexes by actinomycin D
19. Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: Possible relationship with DNA repair
20. Homocamptothecin, an Ering modified camptothecin analog, generates new topoisomerase Imediated DNA breaks
21. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complexes in patients with upper gastrointestinal malignancies treated with topotecan